



HAL
open science

Acetylcholine induces stem cell properties of gastric cancer cells of diffuse type

Phu Hung Nguyen, Yann Touchefeu, Tony Durand, Philippe Aubert, Emilie Duchalais, Stanislas Bruley Des Varannes, Christine Varon, Michel Neunlist, Tamara Matysiak-Budnik

► To cite this version:

Phu Hung Nguyen, Yann Touchefeu, Tony Durand, Philippe Aubert, Emilie Duchalais, et al.. Acetylcholine induces stem cell properties of gastric cancer cells of diffuse type. *Tumor Biology*, 2018, 40 (9), pp.101042831879902. 10.1177/1010428318799028 . inserm-03004863

HAL Id: inserm-03004863

<https://inserm.hal.science/inserm-03004863>

Submitted on 13 Nov 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Acetylcholine induces stem cell properties of gastric cancer cells of diffuse type

Tumor Biology
September 2018: 1–9
© The Author(s) 2018
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/1010428318799028
journals.sagepub.com/home/tub



Phu Hung Nguyen^{1,2}, Yann Touchefeu^{1,3}, Tony Durand¹, Philippe Aubert¹, Emilie Duchalais^{1,3}, Stanislas Bruley des Varannes^{1,3}, Christine Varon⁴, Michel Neunlist¹ and Tamara Matysiak-Budnik^{1,3} 

Abstract

Gastric cancer is the third leading cause of cancer-related death worldwide, but the mechanisms of gastric carcinogenesis are not completely understood. Recently, the role of cholinergic neuronal pathways in promoting this process has been demonstrated. Our aim was to extend these studies and to evaluate, using an in vitro model of tumorspheres, the effect of acetylcholine on human gastric cancer cells, and the role of acetylcholine receptors and of the nitric oxide pathway, in this effect. The gastric cancer cell line MKN-45 of the diffuse type of gastric cancer was cultured in the presence of acetylcholine, or different agonists or inhibitors of muscarinic and nicotinic acetylcholine receptors, or nitric oxide donor or inhibitor of the nitric oxide pathway, and the number and size of tumorspheres were assessed. The expression of cancer stem cell markers (CD44 and aldehyde dehydrogenase) was also evaluated by immunofluorescence and quantitative reverse transcription polymerase chain reaction. We showed that acetylcholine increased both the number and size of tumorspheres and that this effect was reproduced with both muscarinic and nicotinic acetylcholine receptors agonists and was inhibited by both receptor antagonists. The nitric oxide donor stimulated the tumorsphere formation, while the nitric oxide synthesis inhibitor inhibited the stimulatory effect of acetylcholine. Moreover, acetylcholine increased the expression of stem cell markers on gastric cancer cells. These results indicate that acetylcholine induces the stem cell properties of gastric cancer cells and both muscarinic and nicotinic receptors and a nitrergic pathway might be involved in this effect.

Keywords

Acetylcholine, gastric cancer, cancer stem cells, tumorspheres, muscarinic receptors, nicotinic receptors, nitric oxide

Date received: 14 May 2018; accepted: 8 August 2018

Introduction

Gastric cancer (GC) is the third leading cause of mortality from cancer in men in the world,¹ and despite the progress in treatment, its prognosis remains poor, especially for the diffuse type of this cancer, with an overall 5-year survival rate not exceeding 25%.² The mechanisms of gastric carcinogenesis are not completely understood, although the role of infection by *Helicobacter pylori*, as well as of some dietary factors, has been recognized.³ Recently, the implication of the parasympathetic nervous system (PNS) and cholinergic pathways in the pathogenesis of GC has been demonstrated.

¹Université Bretagne Loire, Université de Nantes, INSERM U1235, TENS, Institut des Maladies de l'Appareil Digestif du CHU, Nantes, France

²Faculty of Biotechnology, Thai Nguyen University of Sciences, Thai Nguyen, Vietnam

³Hépatogastroentérologie & Oncologie Digestive, IMAD, Hôtel Dieu, CHU de Nantes, Nantes, France

⁴INSERM U1053, Université de Bordeaux, Bordeaux, France

Corresponding author:

Tamara Matysiak-Budnik, Hépatogastroentérologie & Oncologie Digestive, IMAD, CHU de Nantes, Hôtel Dieu, 1 Place Alexis Ricordeau, 44093 Nantes, France.

Email: tamara.matysiakbudnik@chu-nantes.fr



Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons

Attribution-NonCommercial 4.0 License (<http://www.creativecommons.org/licenses/by-nc/4.0/>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<https://us.sagepub.com/en-us/nam/open-access-at-sage>).

Using three different mice models of gastric carcinogenesis, Zhao et al. have shown that stomach denervation by surgical vagotomy or local injection of neurotoxic agent (botulinum toxin) inhibits the development of gastric tumors and attenuates the progression of preneoplastic lesions into cancer. They have also shown, using an in vitro model of gastric organoids, that acetylcholine (ACh) muscarinic 3 (M3) receptor can modulate gastric stem cells.⁴ In a more recent study,⁵ the same group studied the ACh signaling in transgenic mouse models and showed that nerve- and DCLK1 + tuft cell-derived ACh upregulated nerve growth factor (NGF) which, in turn, stimulated gastric innervation, tumor initiation, and TRK/YAP-mediated gastric stem cell expansion, and that NGF blockage or tuft cell ablation inhibited tumorigenesis. The role of ACh in gastric carcinogenesis was also explored by Yang et al.,⁶ who showed that ACh, through its M3 receptor, promotes the invasion and migration of GC cells through the M3R/AMPK/MACCC1 oncogenic pathway.

All these data strongly indicate that ACh promotes gastric carcinogenesis, but the exact mechanisms (i.e. receptors and signaling pathways involved) are not completely understood. In particular, the possible implication of nicotinic ACh receptors in this process is not clear, although the promoting role of tobacco smoking in GC has been suggested by some epidemiological studies and meta-analyses,^{7,8} and the capacity of alpha-7 nicotinic receptor to stimulate the migration of GC cells has been shown in vitro.⁹ Moreover, the effect of ACh on gastric cancer stem cells (CSCs), as previously suggested,⁴ needs to be further elucidated. Indeed, CSCs represent a unique subpopulation of cells within the tumors, which possess the ability to initiate tumor growth and sustain tumor self-renewal, and which are responsible for cancer recurrence.¹⁰ The existence of CSCs in GC was demonstrated in human GC on the basis of tumorigenic functional assays showing their capacity to initiate tumorsphere formation in vitro, and these cells were essentially characterized by the expression of the cell surface marker CD44 and by high aldehyde dehydrogenase (ALDH) activity.^{11–14}

The nitric oxide (NO) pathway is involved in several effects of ACh. It has been shown that ACh may induce the proliferation of cancer cells by stimulating nitric oxide synthase (NOS) activity¹⁵ and that NOS may activate the muscarinic receptors in different cancer cell lines.¹⁶ It has been also shown that endogenous NO regulates the stemness properties in colon CSCs through cross regulation of several cellular signaling pathways.¹⁷ It is now recognized that NO generated at the inflammatory site may contribute to the initiation and progression of different cancers.¹⁸ All these data suggest that the effects of ACh on GC cell could be, at least in part, mediated by NO.

Therefore, our aim was to study, using an in vitro model of tumorspheres, the effect of ACh on human gastric CSCs, the role of both muscarinic and nicotinic ACh receptors in this effect and the mechanistic role of the NO pathway.

GC cell line culture

Adenocarcinoma gastric epithelial cells MKN-45 (from RIKEN, BRC Cell Engineering Division, Japan) of the diffuse type of GC were cultured in Dulbecco's Modified Eagle Medium (DMEM)/F12 media, with 10% fetal bovine serum and 50 µg/mL vancomycin (all from Invitrogen, Cergy-Pontoise, France) at 37°C in a 5% CO₂ humidified atmosphere, as previously described.¹⁴

Tumorsphere formation

Cells were recovered and 5000 cells were plated on non-adherent 12-well culture plates (coated with a 10% polyHEMA (Sigma, Saint-Quentin-Fallavier, France) solution in absolute ethanol and dried overnight at 56°C). After plating, the cells were incubated for 5 days at 37°C in a serum-free medium consisting of DMEM–F12 GlutaMAX supplemented with 20 ng/mL of epidermal growth factor, 10 ng/mL of basic fibroblast growth factor, 1:100 N₂ supplement 100×, 0.3% glucose, 5 µg/mL of gentamicin, and 50 IU/mL of penicillin (all from Invitrogen).¹⁴ The tumorspheres were identified using an IN Cell Analyzer 2200 microscope system with 20× objective, and the number and size of tumorspheres in each well were quantified using the System snapshot file in IN Cell Analyzer 2200/6000 software. A tumorsphere was defined as a non-adherent cluster of more than 10 cells, as previously described.¹³ The size of tumorspheres was evaluated by measuring the major axis of each tumorsphere using ImageJ software.

Neurotransmitters and cell treatment

ACh, bethanechol (selective ACh muscarinic receptor agonist), dimethylphenylpiperazinium (DMPP; selective ACh nicotinic receptor agonist), atropine (selective ACh muscarinic receptor antagonist), hexamethonium (selective ACh nicotinic receptor antagonist), sodium nitroprusside (SNP; NO donor), and NG-nitro-L-arginine methyl ester (L-NAME; NO synthesis inhibitor), all purchased from Sigma, were used at the concentrations ranging from 0.1 to 10 µM. In different sets of experiments, the cells were cultured in adherent condition in the presence of different neurotransmitters for 5 days, and then the cells were recovered, washed, and cultured without any agent for 7–10 days in non-adherent condition to favor the formation of tumorspheres.

Analysis of the expression of stem cell and epithelial–mesenchymal transition markers

The expression of stem cell (CD44, ALDH1A1, SOX2, KLF4) and epithelial–mesenchymal transition (EMT; Vimentin, Snail1, Zeb1) markers was studied on adherent cells, incubated in the presence of 1 μ M ACh for 5 days.

The expression of CD44, ALDH1A1, Vimentin, Snail1, Zeb1, SOX2, and KLF4 was analyzed by real-time quantitative polymerase chain reaction (RT-qPCR) as previously described.^{14,19} In brief, total cellular RNAs were extracted using the Trizol reagent (Invitrogen) according to the manufacturer's protocol. Total RNA was converted to cDNA using the QuantiTect Reverse Transcription (RT) kit (Qiagen, Courtaboeuf, France) according to the manufacturer's recommendations. Quantitative polymerase chain reaction (PCR) was performed using the SYBR Green qPCR Master Mix (Promega, Charbonnières-les-Bains, France) and specific primers (Cat. No. QT00998333 for CD44, QT0001328 for ALDH1A1, QT00095795 for Vimentin, QT00010010 for Snail1, QT00020972 for Zeb1, QT0023760 for SOX2, and QT00061033 for KLF4, purchased from Qiagen), to analyze the expression of CD44 and ALDH1A1 genes. Real-time PCRs were run on an Applied Biosystems ABI StepOnePlus Real-Time PCR System. Each sample was measured in duplicate. Gene expressions were normalized relative to HPRT1 genes using the comparative Ct method.

In addition, the CD44 expression and ALDH activity were analyzed by immunofluorescence. To this aim, the live adherent cells were incubated in phosphate-buffered saline (PBS) containing anti-CD44 antibody (clone G44-26; BD Biosciences, Le Pont-de-Claix, France) at 4°C for 30 min, washed twice with PBS buffer, and then analyzed using an IN Cell Analyzer 2200 microscope system with 20 \times objective. The activity of ALDH was measured by enzymatic assay using the ALDEFLUOR Kit (STEMCELL Technologies, Grenoble, France), as previously described.¹³

Analysis of the role of the NO pathway in the effect of ACh on GC cells

Cells cultured in adherent condition were treated for 5 days with ACh (1 μ M), SNP (NO donor, 0–1000 μ M), or ACh + L-NAME (NO synthase inhibitor, 10 μ M). After 5 days of treatment, the cells were recovered and cultured in non-adherent condition to evaluate their capacity to form the tumorspheres.

Statistical analysis

Quantitative values represent the mean of three or more independent experiments, each performed in at least

three or more biological replicates, and are expressed as mean \pm standard deviation (SD). Statistics were performed using Mann–Whitney test, Kruskal–Wallis test, or two-way non-parametric analysis of variance (ANOVA) test, depending on the type of comparison, using SPSS 16.0F software (SPSS Inc., Chicago, IL, USA).

Results

ACh induces the CSC properties of GC cells of diffuse type

The primary objective of this study was to determine whether ACh is capable of inducing CSC phenotype in GC cells as assessed by their capacity to form tumorspheres. To this aim, MKN45 cells were treated for 5 days in adherent conditions in the presence of ACh at different concentrations, before being cultured in non-adherent condition for 7–10 days. The impact of ACh was evaluated by the ability of the pretreated cells to form tumorspheres (their number and size).

ACh at the concentrations of 0.1 and 1 μ M significantly increased the number of tumorspheres ($p < 0.0001$ as compared to the control cells, $10 < n < 14$), but this effect was not observed at the highest ACh concentration of 10 μ M (Figure 1(a)–(c)). ACh also significantly increased the size of tumorspheres and this effect was observed at all concentrations ($p < 0.05$, as compared to the control cells, $16 < n < 32$; Figure 1(a), (b), and (d)).

ACh induces the CSC properties of GC cells via muscarinic and nicotinic receptors

The secondary objective was to study, using the pharmacological approach, the involvement of muscarinic and/or nicotinic receptors in the ACh stimulatory effect on the CSC properties of GC cells. First, we showed that the selective ACh muscarinic receptor agonist, bethanechol, increased the number and size of tumorspheres at a concentration of 1 μ M ($*p < 0.05$, $**p < 0.003$, $***p < 0.001$ as compared to the control cells; $n = 7$), but not at the highest (10 μ M) concentration used (Figure 2(a) and (b)). Conversely, the stimulatory effect of ACh on the number and size of tumorspheres was significantly reduced by the muscarinic receptor inhibitor, atropine ($*p < 0.05$, $**p < 0.01$, $***p < 0.001$; $n = 7$; Figure 2(c) and (d)). Second, we showed that DMPP, a selective nicotinic receptor agonist, significantly increased the number and size of tumorspheres at all concentrations (0.1, 1, and 10 μ M) ($*p < 0.05$, $**p < 0.003$, $***p < 0.0003$; $n = 6$; Figure 2(e) and (f)). Conversely, hexamethonium, a nicotinic receptor antagonist, inhibited at a concentration of 100 μ M the stimulatory effect of ACh on tumorsphere




Figure 1. Effect of ACh on tumorsphere formation by GC cells in vitro. GC cells of diffuse type (MKN45) were cultured in adherent condition for 5 days in the presence of ACh at the concentrations of 0.1, 1, or 10 μM and then cultured without ACh for 7–10 days in non-adherent condition to form tumorspheres. Microscopic images (magnification 200 \times) of tumorspheres in control conditions (a) and in the presence of 1 μM ACh (b). The number (c) and size (d) of tumorspheres (mean \pm SE) in control conditions and after treatment with ACh ($10 < n < 14$). ACh at the concentrations of 0.1 and 1 μM increased the number of tumorspheres (***) $p < 0.001$ as compared to the control cells, Kruskal–Wallis test), but this effect disappeared at the highest ACh concentration of 10 μM . ACh at all concentrations increased the size of tumorspheres (d) (* $p < 0.05$ as compared to the control cells, Kruskal–Wallis test, $16 < n < 32$). Scale bars: 100 μM .

formation by diminishing the number and size of tumorspheres as compared to ACh-stimulated cells (* $p < 0.05$, ** $p < 0.03$, *** $p < 0.0001$; $6 < n < 8$; Figure 2(g) and (h)).

The stimulatory effect of ACh on CSC phenotype of GC cells is partly mediated by the NO pathway

We next aimed to identify the possible mechanisms involved in the ACh effects on gastric CSC phenotype and focused on the possible implication of the nitric pathway.

First, we showed that the NO donor, SNP, increased the number and size of tumorspheres at the concentrations of 1, 10, and 100 μM . However, at the highest concentration of 1 mM, SNP completely inhibited the capacity of GC cells to form tumorspheres (* $p < 0.05$, $n = 4$; Figure 3(a)). Conversely, the pretreatment of cells with an NO synthesis inhibitor (L-NAME) significantly inhibited the number of tumorspheres formed by ACh-stimulated cells as compared to L-NAME non-

treated cells (* $p < 0.05$ as compared to ACh-treated cells, *** $p < 0.001$, $n = 7$; Figure 3(b)). Altogether, these results indicate that ACh may act, at least in part, via stimulation of the nitric pathway.

ACh induced CSC and EMT expression markers in GC cells

The self-renewal of stem cells and the EMT are the key events often activated during cancer invasion and metastasis, and associated with the acquisition of stem cell properties.^{20,21} Therefore, we desired to see whether the effect of ACh was associated with the modulation of the expression of CSC and EMT markers in our model. Two stem cell markers were analyzed: CD44, identified as a marker of stem cells of several types, highly expressed in many cancers, including GC, and ALDH1A1, one of the main isoforms of the ALDH isoenzyme family responsible for the activity, recognized as the most specific marker of gastric CSC.^{11,13,22} The expression of the three major EMT markers, Vimentin,




Figure 2. Effect of nicotinic and muscarinic ACh receptors on tumorsphere formation by GC cells in vitro. MKN45 GC cells were cultured in adherent condition for 5 days in the presence of bethanechol (selective ACh muscarinic receptor agonist) (a, b), atropine (selective ACh muscarinic receptor antagonist) (c, d), dimethylphenylpiperazinium (DMPP; selective ACh nicotinic receptor agonist) (e, f), or hexamethonium (selective ACh nicotinic receptor antagonist) (g, h) at the concentrations of 0.1, 1, or 10 μM and then cultured without any agent or with ACh at 1 μM for 7–10 days in non-adherent condition to form tumorspheres. The number (a, c, e, g) and size (b, d, f, h) of tumorspheres (mean \pm SE) in control conditions and after treatment with different agents ($6 < n < 8$) (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ as compared to the non-treated cells, Kruskal–Wallis test). Both agonists (bethanechol and DMPP) at the concentrations of 0.1 and 1 μM increased both the number (a) and size (b) of tumorspheres and this effect was abolished at the highest concentration of 10 μM . DMPP also increased the size of tumorspheres at all concentrations (d). Both ACh receptor antagonists (atropine and hexamethonium) at the concentration of 100 μM inhibited the stimulatory effect of ACh (1 μM) on tumorsphere formation by diminishing the number and size of tumorspheres as compared to ACh-stimulated cells (** $p < 0.01$, *** $p < 0.0001$, two-way non-parametric ANOVA test) (e, f, g, h). These results indicate that both nicotinic and muscarinic receptors are involved in the stimulatory effect of ACh on tumorsphere formation by GC cells.




Figure 3. Effect of NO on tumorsphere formation by the GC cells. Cells were incubated for 5 days in the media with or without sodium nitroprusside (SNP), known as an NO donor. Effect of SNP on tumorsphere formation of GC cells depended on concentration. At low concentrations up to 100 μM , SNP significantly increased the number of tumorspheres as compared to the control condition ($*p < 0.05$, $n = 4$, Mann–Whitney test). In contrast, at the highest concentration of 1000 μM , SNP completely inhibited the capacity of GC cells to form tumorspheres ($\#p < 0.01$ as compared to the control conditions, Mann–Whitney test) (a). In the second part of the experiment (b), the cells were pretreated with ACh (1 μM) and/or an NOS inhibitor L-NAME (10 μM) for 5 days and then cultured in non-adherent condition to form tumorspheres. Inhibition of NOS using L-NAME led to the diminution of the number of tumorspheres formed by ACh-stimulated cells as compared to L-NAME non-treated cells ($*p < 0.05$, $***p < 0.001$ as compared to ACh-treated cells, $n = 7$, two-way non-parametric ANOVA test). These results indicate that the nitroergic pathway may be involved in the stimulatory effect of ACh on tumorsphere formation by GC cells.




Figure 4. Effect of ACh on CSC markers' expression by GC cells. Cells were cultured in adherent condition without or with ACh (1 μM) for 5 days. The expression of CD44 and ALDH was analyzed by RT-qPCR and is expressed as relative mRNA expression fold change as compared to the controls. An increased expression of CD44 (a) and ALDH (b) in ACh-treated cells, as compared to control cells, was observed after 24 h and especially after 48 h of treatment ($*p < 0.05$, $**p < 0.001$, $***p < 0.0001$ by Mann–Whitney test, $n = 3$).

Snail1, and Zeb1, and two self-renewal markers of stem cells, SOX2 and KLF4, was analyzed.¹⁹ Using RT-qPCR, we showed that ACh significantly increased the CD44 and ALDH1A1 mRNA expression levels in GC cells after 24 h and especially after 48 h ($*p < 0.05$, $**p < 0.001$, $***p < 0.0001$, $n = 3$; Figure 4(a) and (b),

respectively). We confirmed this finding on protein level by showing an increased CD44 expression and ALDH activity of GC cells after their incubation with ACh (Figure 5). We also showed that ACh increased the mRNA expression levels of other stem cell markers (SOX2 and KLF4) and also EMT markers (Snail1,




Figure 5. Effect of ACh on CD44 and ALDH expression by immunofluorescence. Cells were cultured in adherent condition without or with ACh (1 μ M) for 5 days. The CD44 protein expression and ALDH activity were analyzed by immunofluorescence. An increased expression of CD44 (a) and ALDH (b) in ACh-treated cells, as compared to the control cells, was observed.

Table 1. Effect of acetylcholine (ACh) on mRNA expression of stem cell markers (SOX2, KLF4) and epithelial–mesenchymal transition markers (Zeb1, Vimentin, Snail1) by gastric cancer cells, after 8, 24, and 48 h of exposure to ACh (1 μ M), determined by RT-qPCR, expressed as median (min–max) of mRNA expression fold change as compared to controls (n = 3).

	8 h	24 h	48 h
SOX2	0.95 (0.63–2.07)	0.98 (0.78–1.19)	12.24 (6.03–38.2)**
KLF4	0.91 (0.69–1.49)*	0.89 (0.49–1.02)*	1.62 (1.14–2.01)**
Zeb1	0.90 (0.65–1.84)	1.27 (0.98–1.65)*	42.25 (23.52–186.3)**
Vimentin	0.82 (0.51–1.3)	1.08 (0.84–1.16)	1.45 (0.85–2.9)*
Snail1	0.79 (0.60–1.24)	0.98 (0.83–1.6)	1.77 (1.07–2.53)*

Significant difference as compared to controls by Mann–Whitney test, *p < 0.02 and **p < 0.0001.

Zeb1, and Vimentin) (*p < 0.02, **p < 0.0001, n = 3; Table 1). These results indicate that ACh induces a CSC phenotype by stimulating the expression of markers of CSC, stem cell self-renewal, and EMT.

Discussion

ACh is the major neurotransmitter of the digestive tract and regulates various physiological processes in the stomach, such as acid and hormonal secretion. Besides its physiological role, ACh and cholinergic pathways could contribute to the development of gastric diseases, and in particular of GC.^{4,5} Indeed, it has been shown that ACh can directly stimulate GC cell proliferation,²³ invasion, and migration⁶ in vitro. Furthermore, Zhao et al.⁴ showed that stomach vagal denervation inhibited GC development and the genetic knockout of M3 receptor–suppressed tumorigenesis in mice. Our results add to these findings by showing that, besides the muscarinic pathways, the nicotinic pathways might also be involved and, additionally, that the ACh effect on CSC

phenotype may be, at least in part, mediated by the NO-dependent pathway.

One of the original findings of our study is that ACh can induce a CSC phenotype in GC cells of the diffuse type. Indeed, most of the previous studies focused on the effect of ACh on the intestinal type of GC.^{4,5} Our study shows that, similarly to what has been observed in the intestinal type of GC, ACh also favors the CSC phenotype of GC cells of the diffuse type as attested by its capacity to increase the number and size of tumourspheres. This effect was in part exerted via the activation of muscarinic receptors since bethanechol reproduced the ACh effect and atropine blocked it. However, we also showed the contribution of the nicotinic-dependent pathways in this effect. This is a particularly important finding since, while the implication of muscarinic receptors in gastric carcinogenesis has been highlighted by several studies,^{4–6,23,24} there are much less data on the potential role of nicotinic receptors in this process. Indeed, the association between GC and tobacco smoking has been demonstrated by epidemiological studies and meta-analyses showing an

increased risk of GC in smokers as compared to non-smokers with a relative risk of about 1.6 and a dose–response relationship.^{8,25} Different pathogenic mechanisms have been proposed, the major one being a direct pro-cancerous effect of several carcinogens included in the tobacco. Nicotine by itself does not appear to have a direct carcinogenic effect, but some data suggest that the stimulation of nicotinic receptors (nicotinic acetylcholine receptor (nAChR)), which are known to participate in cellular adhesion and migration, may promote cell growth and angiogenesis and inhibit the drug-induced apoptosis of cancer cells.^{26,27} We did not specifically look for the nicotinic receptor subtype involved, and future studies will be necessary to identify it. The potential candidates may include an alpha-7 nAChR, already shown to be involved in the migration of GC cells⁹ and in their sensitivity to different chemotherapeutic agents.^{28,29}

The factors involved in the induction of CSC phenotype by ACh in diffuse-type GC cells may include the modulation of CSC markers, such as CD44 and ALDH, and also the enhancement of EMT gene expression by ACh, as demonstrated in our study. CD44 is recognized as a phenotypic marker of CSC, but it also has known functional significance since CD44 siRNA has been shown to drastically inhibit cell survival and tumorsphere formation.¹² EMT enables the cancer cells to disseminate and recent evidence suggested that the induction of EMT is associated with the acquisition of stem cell properties.^{14,20}

Another important finding of our study is the identification of the NO pathway as contributing to the induction of the CSC phenotype by ACh. Indeed, we showed that NO at low concentrations favored the ACh effect, while L-NAME prevented this effect. Similar pro-proliferative properties of NO have been already reported, as well as the deleterious effects of high doses of NO.³⁰ It is worth to notice that low doses of NO are produced during chronic inflammation which could amplify the ACh effects and favor gastric carcinogenesis. In GC, the chronic inflammation driven by *H. pylori* leads to the expression of host inflammatory genes which in turn activate several enzymes, including NOS2, the high expression of which has become an important determinant of gastric carcinogenesis associated with *H. pylori* infection.¹⁸

Our results can also be considered in line with those recently obtained in the experimental models of intestinal type of GC where ACh was shown to mediate its effects via NGF-dependent pathway.⁵ It remains to be shown whether NO could also contribute to the modulation of NGF secretion by ACh.

In conclusion, our results further confirm the role of ACh in gastric carcinogenesis and indicate its capacity of inducing stem cell phenotype in GC cells of diffuse type of GC. They also point to the possible role of the

nitroergic pathway and of nicotinic receptors in this effect, which could become new therapeutic targets in GC in the future.

Acknowledgements

Michel Neunlist and Tamara Matysiak-Budnik share co-senior authorship.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by the French National Society of Gastroenterology (SNFGE), la Ligue Contre le Cancer, SANTEDIGE Foundation, and the Ministry of Science and Technology in Vietnam (grant no. 55/B2017-TNA-55).

ORCID iD

Tamara Matysiak-Budnik  <https://orcid.org/0000-0003-0780-6261>

References

1. Torre LA, Siegel RL, Ward EM, et al. Global cancer incidence and mortality rates and trends—an update. *Cancer Epidemiol Biomarkers Prev* 2016; 25: 16–27.
2. Petrelli F, Berenato R, Turati L, et al. Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis. *J Gastrointest Oncol* 2017; 8: 148–163.
3. Mégraud F, Bessède E and Varon C. *Helicobacter pylori* infection and gastric carcinoma. *Clin Microbiol Infect* 2015; 21: 984–990.
4. Zhao CM, Hayakawa Y, Kodama Y, et al. Denervation suppresses gastric tumorigenesis. *Sci Transl Med* 2014; 6: 250ra115.
5. Hayakawa Y, Sakitani K, Konishi M, et al. Nerve growth factor promotes gastric tumorigenesis through aberrant cholinergic signaling. *Cancer Cell* 2017; 31: 21–34.
6. Yang T, He W, Cui F, et al. MACC1 mediates acetylcholine-induced invasion and migration by human gastric cancer cells. *Oncotarget* 2016; 7: 18085–18094.
7. La Torre G, Chiaradia G, Gianfagna F, et al. Smoking status and gastric cancer risk: an updated meta-analysis of case-control studies published in the past ten years. *Tumori* 2009; 95: 13–22.
8. Praud D, Rota M, Pelucchi C, et al. Cigarette smoking and gastric cancer in the Stomach Cancer Pooling (StoP) project. *Eur J Cancer Prev* 2018; 27: 124–133.
9. Wang W, Chin-Sheng H, Kuo LJ, et al. NNK enhances cell migration through $\alpha 7$ -nicotinic acetylcholine receptor accompanied by increased of fibronectin expression in gastric cancer. *Ann Surg Oncol* 2012; 19(Suppl. 3): S580–S588.

10. Clevers H. The cancer stem cell: premises, promises and challenges. *Nat Med* 2011; 17: 313–319.
11. Nishikawa S, Konno M, Hamabe A, et al. Aldehyde dehydrogenase high gastric cancer stem cells are resistant to chemotherapy. *Int J Oncol* 2013; 42(4): 1437–1442.
12. Takaishi S, Okumura T, Tu S, et al. Identification of gastric cancer stem cells using the cell surface marker CD44. *Stem Cells* 2009; 27: 1006–1020.
13. Nguyen PH, Giraud J, Chambonnier L, et al. Characterization of biomarkers of tumorigenic and chemoresistant cancer stem cells in human gastric carcinoma. *Clin Cancer Res* 2017; 23: 1586–1597.
14. Bessède E, Staedel C, Acuña Amador LA, et al. Helicobacter pylori generates cells with cancer stem cell properties via epithelial-mesenchymal transition-like changes. *Oncogene* 2014; 33: 4123–4131.
15. Fiszman GL, Middonno MC, de la Torre E, et al. Activation of muscarinic cholinergic receptors induces MCF-7 cells proliferation and angiogenesis by stimulating nitric oxide synthase activity. *Cancer Biol Ther* 2007; 6: 1106–1113.
16. Español A, Eiján AM, Mazzoni E, et al. Nitric oxide synthase, arginase and cyclooxygenase are involved in muscarinic receptor activation in different murine mammary adenocarcinoma cell lines. *Int J Mol Med* 2002; 9: 651–657.
17. Puglisi MA, Cenciarelli C, Tesori V, et al. High nitric oxide production, secondary to inducible nitric oxide synthase expression, is essential for regulation of the tumour-initiating properties of colon cancer stem cells. *J Pathol* 2015; 236: 479–490.
18. De Oliveira GA, Cheng RYS, Ridnour LA, et al. Inducible nitric oxide synthase in the carcinogenesis of gastrointestinal cancers. *Antioxid Redox Signal* 2017; 26: 1059–1077.
19. Nguyen PH, Giraud J, Staedel C, et al. All-trans retinoic acid targets gastric cancer stem cells and inhibits patient-derived gastric carcinoma tumor growth. *Oncogene* 2016; 35: 5619–5628.
20. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. *Cell* 2008; 133: 704–715.
21. Radisky DC and LaBarge MA. Epithelial-mesenchymal transition and the stem cell phenotype. *Cell Stem Cell* 2008; 2: 511–512.
22. Wu D, Mou YP, Chen K, et al. Aldehyde dehydrogenase 3A1 is robustly upregulated in gastric cancer stem-like cells and associated with tumorigenesis. *Int J Oncol* 2016; 49: 611–622.
23. Yu H, Xia H, Tang Q, et al. Acetylcholine acts through M3 muscarinic receptor to activate the EGFR signaling and promotes gastric cancer cell proliferation. *Sci Rep* 2017; 7: 40802.
24. Wang L, Zhi X, Zhang Q, et al. Muscarinic receptor M3 mediates cell proliferation induced by acetylcholine and contributes to apoptosis in gastric cancer. *Tumour Biol* 2016; 37: 2105–2117.
25. Lee PN and Hamling J. The relation between smokeless tobacco and cancer in Northern Europe and North America. A commentary on differences between the conclusions reached by two recent reviews. *BMC Cancer* 2009; 9: 256.
26. Schuller HM. Is cancer triggered by altered signalling of nicotinic acetylcholine receptors? *Nat Rev Cancer* 2009; 9: 195–205.
27. Li LF, Chan RL, Lu L, et al. Cigarette smoking and gastrointestinal diseases: the causal relationship and underlying molecular mechanisms (review). *Int J Mol Med* 2014; 34: 372–380.
28. Chen WY, Huang CY, Cheng WL, et al. Alpha 7-nicotinic acetylcholine receptor mediates the sensitivity of gastric cancer cells to 5-fluorouracil. *Tumour Biol* 2015; 36: 9537–9544.
29. Tu CC, Huang CY, Cheng WL, et al. The $\alpha 7$ -nicotinic acetylcholine receptor mediates the sensitivity of gastric cancer cells to taxanes. *Tumour Biol* 2016; 37: 4421–4428.
30. Choudhari SK, Chaudhary M, Bagde S, et al. Nitric oxide and cancer: a review. *World J Surg Oncol* 2013; 11: 118.